Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 29, 2012 | March 02, 2012 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 29, 2012 · Filed March 02, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 229,617 |
Ending reported balance
After 2012-02-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2012-02-29 · Tax withholding · Disposed 15,954 · Balance 231,144 Row 2 · 2012-02-29 · Sale · Disposed 1,527 · Balance 229,617 |
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
| Restricted Stock Units (Converted)SEC Table II · derivative / convertible security | Direct | 3,513 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 3,513 · Balance 3,513 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 878 shares vested on June 25, 2026, 878 shares will vest on September 25, 2026, 878 shares will vest on December 25, 2026, and 879 shares will vest on March 25, 2027. |
| Restricted Stock Units (Premium)SEC Table II · derivative / convertible security | Direct | 1,053 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Grant · Acquired 1,053 · Balance 1,053 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
F4: 878 shares vested on June 25, 2026, 878 shares will vest on September 25, 2026, 878 shares will vest on December 25, 2026, and 879 shares will vest on March 25, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 9,098 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 1,137 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 341 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 356 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 106 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 555 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 166 · Balance 0 F2: Each restricted stock unit represents the right to receive one share of Quidel common stock. F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F3: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F4: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2010 Filed Feb 18, 2010 23:25 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,044 | $53.93 | $272,022.92 |
DisclosureSEC source: 0001179110-10-003155 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,640 Read SEC document |
| December 31, 2009 Filed Jan 5, 2010 22:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 7,890 | $54.54 | $430,320.60 |
DisclosureSEC source: 0001179110-10-000405 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,684 Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 29,970 | $0.00 Strike: $32.61 | $0.00 |
DisclosureSEC source: 0001179110-09-012889 · edgar.xml · derivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 29,970 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,100 | $45.02 | $49,522.00 |
DisclosureSEC source: 0001179110-09-012889 · edgar.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,574 Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,100 | $45.01 | $364,581.00 |
DisclosureSEC source: 0001179110-09-012889 · edgar.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,674 Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 20,770 | $45.00 | $934,650.00 |
DisclosureSEC source: 0001179110-09-012889 · edgar.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,774 Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 29,970 | $32.61 | $977,354.67 |
DisclosureSEC source: 0001179110-09-012889 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2009 Filed Jul 31, 2009 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 711 | $45.69 | $32,485.59 |
DisclosureSEC source: 0001179110-09-011405 · edgar.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,574 Read SEC document |
| February 27, 2009 Filed Mar 4, 2009 00:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,708 | $50.58 | $288,710.64 |
DisclosureSEC source: 0001104659-09-013947 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,285 Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 64,900 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001104659-09-011816 · a4.xml · derivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,900 Underlying: Common shares · 64,900 shares Expires 2019-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,634 on 02/20/2010, 21,633 on 02/20/2011, and 21,633 on 02/20/2012. Read SEC document |
| February 20, 2009 Filed Feb 24, 2009 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 45,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-011816 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,993 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 17, 2009 Filed Feb 19, 2009 17:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,718 | $54.94 | $94,386.92 |
DisclosureSEC source: 0001104659-09-010669 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,193 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 34,873 | $0.00 Strike: $54.40 | $0.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · derivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 34,873 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $55.45 | $49,905.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,911 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,300 | $55.44 | $238,392.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,811 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,000 | $55.43 | $55,430.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,111 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 13,500 | $55.42 | $748,170.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,111 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,900 | $55.41 | $271,509.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,611 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,273 | $55.40 | $569,124.20 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,511 Read SEC document |
| February 02, 2009 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 34,873 | $54.40 | $1,897,091.20 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2008 Filed Feb 5, 2009 01:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-006485 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,911 Read SEC document |
| July 30, 2008 Filed Aug 1, 2008 21:59 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 711 | $55.94 | $39,773.34 |
DisclosureSEC source: 0001104659-08-049358 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,411 Read SEC document |
| July 15, 2008 Filed Jul 17, 2008 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,973 | $56.22 | $110,922.06 |
DisclosureSEC source: 0001104659-08-046178 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,122 Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 17,113 | $0.00 Strike: $54.40 | $0.00 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · derivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,113 Underlying: Common Shares · 17,113 shares Expires 2010-02-10 F1 · security: Employee stock option, including replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 34,873 | $0.00 Strike: $54.40 | $0.00 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · derivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,873 Underlying: Common Shares · 34,873 shares Expires 2009-02-11 F1 · security: Employee stock option, including replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,065 | $0.00 Strike: $32.61 | $0.00 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · derivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,065 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option, including replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 20,167 | $0.00 Strike: $32.61 | $0.00 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · derivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,970 Underlying: Common Shares · 20,167 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option, including replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 40,433 | $0.00 Strike: $42.50 | $0.00 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · derivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 40,433 shares Expires 2009-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option, including replacement option feature, granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 51,986 | $54.40 | $2,828,038.40 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,095 Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,232 | $32.61 | $757,621.08 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 40,433 | $42.50 | $1,718,313.55 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2008 Filed May 16, 2008 22:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,936 | $55.00 | $546,480.00 |
DisclosureSEC source: 0001104659-08-034127 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,416 Read SEC document |
| February 29, 2008 Filed Mar 5, 2008 01:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,683 | $54.22 | $145,472.26 |
DisclosureSEC source: 0001104659-08-015213 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,352 Read SEC document |
| February 19, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 373 | $56.09 | $20,922.69 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,035 Read SEC document |
| February 19, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 445 | $56.09 | $24,960.05 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,408 Read SEC document |
| February 18, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 740 | $55.55 | $41,107.00 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,853 Read SEC document |
| February 17, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,718 | $55.55 | $95,434.90 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,593 Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 93,400 | $0.00 Strike: $55.56 | $0.00 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · derivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,400 Underlying: Common shares · 93,400 shares Expires 2018-02-14 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 31,134 on 02/15/2009, 31,133 on 02/15/2010, and 31,133 on 02/15/2011. Read SEC document |
| February 15, 2008 Filed Feb 20, 2008 23:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,000 | $55.56 | $1,277,880.00 |
DisclosureSEC source: 0001104659-08-011831 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,311 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 31,045 | $0.00 Strike: $54.30 | $0.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · derivative · entry 9 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,045 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $56.17 | $22,468.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 8 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,311 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $56.16 | $84,240.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 7 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,711 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 745 | $56.15 | $41,831.75 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 6 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,211 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,700 | $56.13 | $151,551.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 5 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,956 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $56.12 | $123,464.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 4 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,656 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,000 | $56.11 | $168,330.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,856 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 20,500 | $56.10 | $1,150,050.00 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,856 Read SEC document |
| February 11, 2008 Filed Feb 12, 2008 23:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 31,045 | $54.30 | $1,685,743.50 |
DisclosureSEC source: 0001104659-08-009504 · a4.xml · nonDerivative · entry 1 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2007 Filed Aug 21, 2007 19:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,875 | $0.00 Strike: $34.77 | $0.00 |
DisclosureSEC source: 0001104659-07-063971 · a4.xml · derivative · entry 3 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,875 shares Expires 2008-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 20, 2007 Filed Aug 21, 2007 19:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,895 | $52.73 | $99,923.35 |
DisclosureSEC source: 0001104659-07-063971 · a4.xml · nonDerivative · entry 2 Michael Edward L · CIK 0001391823 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,311 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.